8-K Announcements
6Material company update
Sep 14, 2026·SEC
Material company update
Sep 8, 2026·SEC
Material company update
Aug 12, 2026·SEC
MindMed is currently in a high-stakes, pre-revenue development phase, with its valuation heavily contingent on the successful progression of the MM-120 candidate through Phase 3 clinical trials.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest Mar 5, 2026 | -$0.51-6.3% vs -$0.48 | — vs — |
Q4 2025 Nov 6, 2025 | -$0.78-50.0% vs -$0.52 | — vs — |
Q3 2025 Jul 31, 2025 | -$0.50-31.6% vs -$0.38 | — vs — |
Q2 2025 May 8, 2025 | -$0.35+2.8% vs -$0.36 | — vs — |
Benchmark DFTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Definium Therapeutics, Inc. (DFTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $33.27 | $4.47B | -10.41 | — | — | -85.23% | — | |
| $8.61 | $1.16B | -5.26 | — | — | -212.85% | — | |
| $8.96 | $555.38M | -2.56 | -9561.61% | — | -70.99% | — | |
| $0.19 | $3.31M | -0.22 | -25.96% | -4791.48% | -106.13% | — | |
| $1.33 | $1.5M | -0.33 | — | -8269.53% | -81.74% | — | |
| $21.65 | $330.85M | 30.45 | 13.74% | 4.48% | 12.66% | — |
Definium Therapeutics, Inc. (DFTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Definium Therapeutics, Inc. (DFTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Sep 14, 2026·SEC
Sep 8, 2026·SEC
Aug 12, 2026·SEC
Get notified when DFTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Definium Therapeutics, Inc. (DFTX) stock FAQ — growth, dividends, profitability & financials explained
No. Definium Therapeutics, Inc. (DFTX) reported a net loss of $353.8M over the trailing twelve months.
Definium Therapeutics, Inc. (DFTX) had a return on equity (ROE) of -85.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Definium Therapeutics, Inc. (DFTX) had negative free cash flow of $166.9M over the trailing twelve months.